A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Author： Garcia Jorge A.   Hudes Gary R.   Choueiri Toni K.   Stadler Walter M.   Wood Laura S.   Gurtler Jayne   Bhatia Shailender   Joshi Adarsh   Hozak Rebecca R.   Xu Yihuan   Schwartz Jonathan D.   Thompson John A.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|11|1647-1655

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.11, 2014-06, pp. : 1647-1655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By Stadler Walter M.   Vaughn David J.   Sonpavde Guru   Vogelzang Nicholas J.   Tagawa Scott T.   Petrylak Daniel P.   Rosen Peter   Lin Chia-Chi   Mahoney John   Modi Sanjiv   Lee Peter   Ernstoff Marc S.   Su Wu-Chou   Spira Alexander   Pilz Korinna   Vinisko Richard   Schloss Charles   Fritsch Holger   Zhao Charles   Carducci Michael A.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

Blackwell Publishing

Access to resources Recommend Favorite

Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

By Pal Sumanta K.   Figlin Robert A.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1604-1607

Blackwell Publishing

Access to resources Recommend Favorite

Pazopanib: The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

By Keisner Sidney V.   Shah Sachin R.  

Drugs, Vol. 71, Iss. 4, 2011-03 ,pp. : 443-454

Adis International

Access to resources Recommend Favorite

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

By Goldstein D.   Ackland S.   Bell D.   Olver I.   Davis I.   Rosenthal M.   Toner G.   Pinel M.   Byrne M.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 429-434

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1501-1510

Springer Publishing Company

Access to resources Recommend Favorite